Skip to main content

News Releases

Menu
Press Release RSS Feed (opens in new window)
Press release year list 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013
December 29, 2020
Clovis Oncology Submits Investigational New Drug Applications for Novel Peptide-Targeted Radionuclide FAP-2286 for Therapeutic and Imaging Clinical Trial Download PDF format download (opens in new window)
December 21, 2020
Clovis Oncology’s Rubraca® (rucaparib) Met the Primary Endpoint of Significantly Improving Progression-Free Survival vs. Chemotherapy in the ARIEL4 Randomized Phase 3 Treatment Study in Later-line Ovarian Cancer Patients with a BRCA mutation Download PDF format download (opens in new window)
November 24, 2020
Clovis Oncology Announces Exercise by Existing Holder of Option to Purchase an Additional $7.5 Million Aggregate Principal Amount of the Company’s 4.50% Convertible Senior Notes Due 2024 Download PDF format download (opens in new window)
November 20, 2020
Clovis Oncology to Present at the Piper Sandler 32nd Annual Healthcare Conference Download PDF format download (opens in new window)
November 5, 2020
Clovis Oncology Announces Third Quarter 2020 Operating Results Download PDF format download (opens in new window)
November 5, 2020
Clovis Oncology Announces Debt Exchange Transaction and Offering of Convertible Senior Notes Download PDF format download (opens in new window)
October 20, 2020
Clovis Oncology to Announce Third Quarter 2020 Financial Results and Host Webcast Conference Call on November 5 Download PDF format download (opens in new window)
September 17, 2020
New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline Download PDF format download (opens in new window)
September 10, 2020
Clovis Oncology Announces Oral Plenary Session Presentation at International Gynecologic Cancer Society (IGCS) Digital Annual Global Meeting Download PDF format download (opens in new window)
September 9, 2020
Clovis Oncology to Highlight Data for its Three Portfolio Compounds at the ESMO Virtual Congress 2020 Download PDF format download (opens in new window)
September 8, 2020
Clovis Oncology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference Download PDF format download (opens in new window)
August 26, 2020
FDA Approves FoundationOne® Liquid CDx to Serve as Rubraca® (rucaparib) Companion Diagnostic to Identify Eligible Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC) Download PDF format download (opens in new window)
August 17, 2020
Journal of Clinical Oncology Publishes Additional Data from Clovis Oncology’s TRITON2 Clinical Trial Evaluating Rubraca® (rucaparib) for the Treatment of mCRPC in Patients with BRCA1/2 Gene Mutations Download PDF format download (opens in new window)
August 6, 2020
Clovis Oncology Announces Second Quarter 2020 Operating Results Download PDF format download (opens in new window)
August 5, 2020
Clovis Oncology Announces First Patient Enrolled in the Phase 2 Portion of the LIO-1 Trial Evaluating the Combination of Lucitanib and Opdivo in Gynecologic Cancers Download PDF format download (opens in new window)
July 23, 2020
Clovis Oncology to Announce Second Quarter 2020 Financial Results and Host Webcast Conference Call on August 6 Download PDF format download (opens in new window)
June 22, 2020
New Preclinical Data on ALKS 4230 in Combination With Lucitanib to be Presented at 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II Download PDF format download (opens in new window)
June 17, 2020
Clovis Oncology to Highlight Rubraca® (rucaparib) and Lucitanib Non-Clinical Data at the AACR Virtual Annual Meeting II 2020 Download PDF format download (opens in new window)
June 10, 2020
Clovis Oncology Announces Completion of Target Enrollment in the ATHENA Trial, a Phase 3 Maintenance Treatment Study in Front-line, Newly-Diagnosed Advanced Ovarian Cancer Download PDF format download (opens in new window)
May 28, 2020
Clovis Oncology Announces New Recommendations for Rubraca® (rucaparib) Tablets in Updated National Comprehensive Cancer Network (NCCN) Guidelines® for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Download PDF format download (opens in new window)
May 21, 2020
Clovis Oncology Announces Presentations at 2020 ASCO Virtual Scientific Program
May 18, 2020
Clovis Oncology Announces Pricing of Public Offering of Common Stock Download PDF format download (opens in new window)
May 18, 2020
Clovis Oncology Announces Proposed Offering of Common Stock Download PDF format download (opens in new window)
May 15, 2020
Rubraca® (Rucaparib) Approved in the U.S. as Monotherapy Treatment for Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Been Treated with Androgen Receptor-Directed Therapy and a Taxane-Based Chemotherapy Download PDF format download (opens in new window)
May 5, 2020
Clovis Oncology Announces First Quarter 2020 Operating Results Download PDF format download (opens in new window)
April 29, 2020
Clovis Oncology to Present at the Bank of America Health Care Conference 2020 Download PDF format download (opens in new window)
April 21, 2020
Clovis Oncology to Announce First Quarter 2020 Financial Results and Host Webcast Conference Call on May 5 Download PDF format download (opens in new window)
April 14, 2020
Clovis Oncology Announces Debt Exchange Transaction Download PDF format download (opens in new window)
March 3, 2020
Clovis Oncology to Present at the Barclays Global Healthcare Conference Download PDF format download (opens in new window)
March 2, 2020
Clovis Oncology Announces Availability and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Spain Download PDF format download (opens in new window)
February 24, 2020
Clovis Oncology Announces 2019 Operating Results Download PDF format download (opens in new window)
February 13, 2020
Clovis Oncology to Announce Fourth Quarter/Full Year 2019 Financial Results and Host Webcast Conference Call on February 24 Download PDF format download (opens in new window)
February 11, 2020
Clovis Oncology to Present at the 9th Annual SVB Leerink Healthcare Conference Download PDF format download (opens in new window)
February 3, 2020
Clovis Oncology Announces Availability and Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in France Download PDF format download (opens in new window)
January 15, 2020
Clovis Oncology’s Rubraca® (rucaparib) Granted FDA Priority Review for Advanced Prostate Cancer Download PDF format download (opens in new window)
January 7, 2020
Clovis Oncology Announces Debt Refinancing Transaction Download PDF format download (opens in new window)
January 7, 2020
Clovis Oncology Announces Product Revenues for the Fourth Quarter and Full Year 2019 Download PDF format download (opens in new window)